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Summ a r y
Ketoacidosis is a potentially lethal condition caused by the imbalance between he-
patic production and extrahepatic utilization of ketone bodies. We performed exome 
sequencing in a patient with recurrent, severe ketoacidosis and identified a homozy-
gous frameshift mutation in the gene encoding monocarboxylate transporter 1 
(SLC16A1, also called MCT1). Genetic analysis in 96 patients suspected of having 
ketolytic defects yielded seven additional inactivating mutations in MCT1, both homo-
zygous and heterozygous. Mutational status was found to be correlated with keto-
acidosis severity, MCT1 protein levels, and transport capacity. Thus, MCT1 deficiency 
is a novel cause of profound ketoacidosis; the present work suggests that MCT1-
mediated ketone-body transport is needed to maintain acid–base balance.
Acetoacetate and 3-hydroxybutyrate are slightly acidic biomol-ecules that, together with acetone, are called ketone bodies and serve as the major circulating energy source during fasting. Ketone bodies are formed in 
the liver from the ultimate breakdown product of fatty acids — acetyl coenzyme A 
(CoA) — by coupling of two acetyl units in a three-step enzymatic process called 
ketogenesis. Ketone bodies are believed to undergo passive distribution to meta-
bolically active tissues, where they are used as an energy source.1
Ketoacidosis, a pathologic state, occurs when ketone formation exceeds ketone 
utilization. The clinical consequences of ketoacidosis are exemplified by diabetic 
ketoacidosis, a condition that is marked by vomiting, osmotic diuresis, dehydration, 
and Kussmaul breathing and that may progress to decreased consciousness and, 
ultimately, death.2
Inborn errors of ketone utilization are manifested similarly; however, glucose 
levels in these types of ketoacidosis are normal or even low, in contrast to glucose 
levels in diabetic ketoacidosis.3 Only two genetic causes of recurrent ketoacidosis 
are currently known: succinyl CoA oxoacid transferase (SCOT) deficiency (Online 
Mendelian Inheritance in Man [OMIM] database number, 245050) and mitochondrial 
acetoacetyl-CoA thiolase (ACAT1) deficiency (also called beta-ketothiolase deficiency; 
OMIM number, 203750). Both SCOT and ACAT1 are involved in ketolysis, the break-
down of ketone bodies into the key cellular energy source, acetyl CoA.
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We performed targeted exome sequencing of 
homozygous genomic regions in a patient of con-
sanguineous descent who had recurrent, severe 
ketoacidosis. A homozygous mutation was detect-
ed in the gene encoding monocarboxylate trans-
porter 1 (MCT1). Subsequently, we evaluated a se-
ries of 96 patients with recurrent ketoacidosis, in 
whom known ketolytic defects had been ruled out 
enzymatically, to identify additional patients with 
mutations in MCT1 or related genes.
Me thods
Study Participants and Genetic Studies
We performed targeted exome sequencing of ho-
mozygous genomic regions in the index patient 
and her family members. Regions of homozygos-
ity in the index patient were determined with the 
use of a high-resolution single-nucleotide poly-
morphism (SNP) array. Coding parts of homozy-
gous regions were then captured on a custom array 
and sequenced as described elsewhere.4,5 To follow 
up on the findings from exome sequencing, we 
sequenced the entire coding region of MCT1 in a 
series of 96 patients with ketoacidosis in whom 
known ketolytic defects had been ruled out be-
cause of the normal enzymatic activities of ACAT1 
and SCOT. In addition, we performed Sanger se-
quencing of the related genes MCT2 (SLC16A7), 
MCT3 (SLC16A8), and MCT4 (SLC16A3), plus the an-
cillary gene BSG, in these patients. Heterozygosity 
of mutations was confirmed by means of com-
plementary DNA (cDNA) sequencing and genomic 
deletion analysis.
Further details of sequencing and analysis are 
available in the Supplementary Appendix, avail-
able with the full text of this article at NEJM.org. 
Written informed consent for targeted whole-
exome sequencing and Sanger sequencing was 
obtained from the parents of the index patient 
for themselves, the index patient, and her two 
siblings. Sanger sequencing of candidate genes in 
the cohort of patients with a suspected ketolytic 
defect and blood collection for functional studies 
were performed as a part of the diagnostic pro-
cess (approved by the medical ethics committee of 
the University Medical Center Utrecht).
MCT1 Expression and Functional Studies
Erythrocyte lactate transport was measured es-
sentially as described by Fishbein.6 For the analy-
sis of each blood sample from a patient, at least 
one control sample was included in the same ex-
periment, with the same procedures used for 
blood collection, transport, and analysis. Control 
blood samples were taken at random from blood 
left over from diagnostic tests, which was used 
anonymously in this study. Immunoblotting was 
performed with fibroblast homogenates and an 
affinity-purified rabbit polyclonal antibody against 
MCT1 and MCT4. Fibroblast homogenates from 
10 healthy volunteers were also used as controls. 
Further details on functional and expression stud-
ies are available in the Supplementary Appendix. 
Reference blood results from testing of children 
before and after 24 hours of fasting were obtained 
from published data.7
Statistical Analysis
All applied statistical tests were two-tailed un-
paired t-tests. P values of less than 0.05 were con-
sidered to indicate statistical significance.
R esult s
Case Report
The index patient had repetitive episodes of pro-
found metabolic acidosis, with a blood pH below 
7.00 on three occasions, all accompanied by mas-
sive urinary excretion of 3-hydroxybutyrate and 
acetoacetate, with plasma lactate and ammonia 
levels remaining in the normal range. Between 
episodes, results of blood gas analyses were nor-
mal. See the Supplementary Appendix for an ex-
tended case report.
Genetic Studies
SNP array analysis in the index patient revealed 
36 homozygous genomic regions larger than 1 Mb, 
with 7 of the 36 larger than 10 Mb, which con-
firmed consanguinity. Targeted exome sequenc-
ing of coding parts of these homozygous regions 
in the five family members yielded nine rare 
variants. Of these, a single-nucleotide insertion 
disrupting the reading frame of MCT1 at aspara-
gine 15 (c.41dupC; National Center for Biotech-
nology Information reference sequence number, 
NM_001166496.1) was the strongest candidate. 
The correct segregation of this mutation in the 
family was confirmed by means of Sanger se-
quencing. This variant was absent from multiple 
large variation databases (1000 Genomes, dbSNP, 
and the National Heart, Lung, and Blood Institute 
[NHLBI] GO Exome Sequencing Project Exome 
Variant Server [data release ESP6500]). The inser-
tion of an extra nucleotide early in the gene se-
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quence results in a frameshift and thus in a loss 
of MCT1 function.
MCT1 Mutations in Additional Patients  
with Ketoacidosis
MCT1 is one of the transmembrane transporters 
encoded by members of the SLC16 gene family; 
among these transmembrane transporters, MCT1, 
MCT2, MCT3, and MCT4 have been shown to 
transport monocarboxylates, including lactate and 
ketone bodies.8 MCT1 requires the glycoprotein 
BSG (also called CD147) for proper subcellular 
expression.9,10 We therefore sequenced MCT1 and 
related genes in a series of 96 patients with un-
explained ketoacidosis. We identified seven ad-
ditional suspected deleterious variants, all in MCT1, 
including six truncating mutations and one mis-
sense mutation (Fig. 1A and Table 1). All trun-
cating mutations are expected to result in a loss 
of protein function. The missense mutation, 
p.Arg313Gln, targets a highly conserved residue 
that is essential for catalytic activity.11 In total, 
we identified 9 patients with mutations in 
MCT1, 3 homozygous and 6 heterozygous, includ-
ing 2 siblings. None of these mutations were seen 
previously in population-based variation databases 
(1000 Genomes, dbSNP, NHLBI GO Genome Se-
quencing Project Exome Variant Server, and Ge-
nome of the Netherlands).12 Together, the genetic 
data firmly link defects in MCT1 to ketoacidosis 
in our patients.
MCT1 Expression
Next, we studied the effect of the mutations in 
MCT1 at the protein level. Immunoblot analysis 
with fibroblast homogenates from patients with 
a homozygous MCT1 mutation, performed with 
antibodies raised against a C-terminal peptide of 
MCT1, confirmed that predicted truncating mu-
tations lead to an absence of the full-length pro-
tein (Fig. S1A in the Supplementary Appendix). 
In five patients, we could detect only a single het-
erozygous truncating mutation in MCT1 (Fig. 1A), 
despite sequencing the complete coding region. 
Analysis of cDNA confirmed biallelic expression 
(Fig. 1B). A custom multiplex amplification quan-
tification analysis further ruled out the presence 
of exon-sized deletions in heterozygous patients. 
Immunoblot analysis showed significantly reduced 
levels of MCT1 protein in fibroblasts from patients 
with a heterozygous truncating mutation, relative 
to levels in controls (Fig. 1C, and Fig S1B in the 
Supplementary Appendix). The immunoblot results 
confirmed that there was an MCT1 deficiency at 
the protein level. We tested fibroblasts to deter-
mine whether the MCT1 deficiency was compen-
sated for by increased cellular expression of MCT4 
but found no evidence for this (Fig S1C in the 
Supplementary Appendix).
Monocarboxylate Transport Assay
Next, we studied the effect of mutations in MCT1 
on monocarboxylate transport, using a previously 
described assay for MCT1 activity that measures 
lactate efflux from erythrocytes endogenously 
loaded with lactate.6,13 In the samples from pa-
tients with a homozygous mutation in MCT1, 
erythrocyte lactate transport was significantly 
reduced as compared with that in the control 
samples (Fig. 1D). The mean lactate transport ac-
tivity in erythrocytes from heterozygous carriers, 
both symptomatic and asymptomatic, was signifi-
cantly reduced as compared with the transport 
activity in control samples but was significantly 
higher than that in homozygous patients (Fig. 1D).
Clinical Symptoms
All patients presented with bouts of ketoacidosis 
provoked by fasting or infections in their first 
years of life (Table 1), as is illustrated for the 
index patient in Figure 2A, and Figure S2A in the 
Supplementary Appendix. The pH of the blood 
was normal between episodes. Excretion of uri-
nary ketones under these circumstances ranged 
from normal to clearly elevated (Fig. 2B). Keto-
acidotic episodes were preceded by poor feeding 
and vomiting and were associated with dehydra-
tion, which was a consequence of osmotic diure-
sis and vomiting. Hypoglycemia was observed 
infrequently, and glucose levels usually remained 
in the normal range (Fig. S2B and S2C in the 
Supplementary Appendix). In some patients, re-
petitive vomiting led to a diagnosis of ketotic 
vomiting or abdominal migraine. Profound met-
abolic acidosis was associated with decreased 
consciousness and insufficient respiratory drive 
(Fig. 2C), which worsened the degree of acidosis.
In all patients, treatment with intravenous 
glucose or dextrose (combined with bicarbonate) 
led to rapid clearance of metabolic acidosis. Early 
initiation of treatment appeared to prevent keto-
acidosis. Similarly, ensuring an adequate caloric 
intake reduced the number of episodes. The fre-
quency of ketoacidotic episodes appeared to de-
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crease over time, and none of the patients had 
documented ketoacidosis after 7 years of age. 
Nevertheless, some patients continued to have 
marked ketonuria associated with (mild) infec-
tions.
Patients with homozygous mutations in MCT1 
tended to present at a younger age (P = 0.05) 
and had more profound ketoacidosis (Fig. 2D, 
and Fig. S2D in the Supplementary Appendix). 
In addition, homozygous patients had mild-to-
moderate developmental delay, whereas patients 
with milder deficiencies of MCT1 had normal 
development.
Discussion
We identified MCT1 deficiency as a disorder of 
ketone utilization, expanding the spectrum of 
disorders leading to ketoacidosis from those of 
ketolysis to those of ketone delivery. This find-
ing may aid in timely diagnosis of the disorder 
and allow for improved disease management. In 
addition, this observation implies that MCT1-
mediated import of ketone bodies into extrahe-
patic tissues is essential during periods of cata-
bolic stress in order to maintain acid–base 
balance.
Figure 1. MCT1 Deficiency in Patients with Episodes of Ketoacidosis.
Panel A shows the identified mutations in the monocarboxylate transporter 1 (MCT1) protein, with the four differ­
ent exons indicated. The full­length MCT1 protein consists of 500 amino acids. Heterozygous mutations are indicat­
ed in gray, and homozygous mutations in black. Panel B shows examples of the sequencing of complementary DNA 
in fibroblasts from patients with heterozygous mutations; the colors represent bases: green denotes A, red T, black 
G, and blue C. The arrows indicate the mutated residue. The majority of the transcript is unmutated MCT1 se­
quence, and the minority is the mutated sequence as a result of nonsense­mediated decay. Panel C shows the 
MCT1:tubulin ratio from a quantitative immunoblot with fibroblast homogenates from 4 patients with heterozygous 
truncating mutations as compared with 10 healthy controls. Panel D shows lactate efflux from erythrocytes endoge­
nously loaded with lactate. Efflux was measured for patients with a homozygous MCT1 mutation and their hetero­
zygous family members (solid circles denote p.Arg313Ter, squares p.Arg328Ter, and triangles p.Asp15fs), a hetero­
zygous patient (p.Arg313Gln, denoted by the diamond), and controls (denoted by open circles). The lactate 
transport in the homozygous patients was significantly lower than in both controls and heterozygotes. The mean 
lactate transport activity in heterozygotes was also reduced. Horizontal bars indicate the mean transport activity.
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Figure 2. Blood Test Results from Patients with MCT1 Deficiency.
Panel A shows the blood pH over time for the index patient (who had the p.Asp15fs mutation). The ketoacidotic 
events are clearly visible. An extended case report for this patient is available in the Supplementary Appendix. Panel 
B shows the 3­β­hydroxybutyrate levels in urine, normalized to creatinine, in three MCT1­deficient patients. Control 
values are less than 10 mmol per mole of creatinine in between episodes and between 160 and 6400 mmol per 
mole of creatinine after 24 hours of fasting. Panel C shows the carbon dioxide excess (actual carbon dioxide concen­
tration minus expected carbon dioxide concentration) versus the pH in homozygous or heterozygous MCT1­defi­
cient patients and controls. The expected carbon dioxide concentration was calculated according to Winter’s formu­
la; the horizontal dotted line indicates the absence of excess carbon dioxide. Data points for the index patient show 
clearly that blood values were within the normal range except during ketotic events. Values during a ketotic event in 
a patient with mitochondrial acetoacetyl­CoA thiolase (ACAT1) deficiency form a separate constellation from the 
values for MCT1­deficient patients. Panel D shows the lowest recorded blood pH value during a ketotic event in ho­
mozygous and heterozygous MCT1­deficient patients and controls. The horizontal bar indicates the mean control 
value. The pH is lower in the homozygous and heterozygous patients than in controls and lower in homozygotes 
than in heterozygotes.
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MCT1 encodes a transmembrane protein that 
facilitates proton-linked transport of a range of 
monocarboxylate metabolites, such as lactate, 
pyruvate, and ketone bodies, across the cellular 
membrane.8 Our observation of profound keto-
acidosis in patients with MCT1 deficiency high-
lights the fact that facilitated transport of ketone 
bodies by MCT1 is essential during catabolic 
stress, when ketone turnover in the body is or-
ders of magnitude higher than in the fed state.
Heterozygous missense mutations in MCT1 
have previously been reported in association with 
suboptimal erythrocyte lactate transport result-
ing in muscle injury on exercise and heat expo-
sure.13 Our patient with a heterozygous missense 
mutation had exercise intolerance, which indicates 
a possible overlapping phenotype. Mutations lead-
ing to increased expression of MCT1 are associ-
ated with exercise-induced hyperinsulinism.14,15
Monocarboxylate transporters show tissue-
specific variation in expression between species,16 
which underlines the importance of insights 
gained in our study of MCT1 function in human 
disease. Homozygous MCT1-knockout mice die 
early during embryogenesis,17,18 in contrast to the 
patients with a complete loss of MCT1 function 
in this study. Mouse placenta and human placenta 
express MCT1 in opposite subcellular arrange-
ments,19 which provides a possible explanation 
for the differences in embryonic lethality. Dis-
ruption of MCT1 in the central nervous system 
produces axon damage and neuronal loss in 
mice.17 The patients with homozygous loss-of-
function mutations in MCT1 described in our 
study have moderate intellectual disability; how-
ever, at this stage it remains unclear whether this 
is a direct effect of the absence of MCT1 in the 
brain or caused by episodes of profound ketoaci-
dosis.
The use of acidic biomolecules as an energy 
source presents a potential threat to acid–base 
homeostasis and therefore requires a careful bal-
ance between production and consumption. This 
aim is achieved indirectly, by linking the rate of 
ketogenesis with cellular energy status in extra-
hepatic tissues. Concerted action of glucagon and 
insulin released by the pancreas determines the 
rate of ketogenesis in the liver. The massive ke-
toacidosis in patients with MCT1 deficiency and 
other disorders of ketone utilization — SCOT 
deficiency and ACAT1 deficiency — unveils the 
weak spot of this indirect feedback mechanism. In 
these disorders, the conversion of ketone bodies to 
acetyl CoA becomes rate limiting. As a conse-
quence, ketone production is uncoupled from con-
sumption, leading to profound metabolic acidosis.
We found that a single heterozygous MCT1 
mutation can result in a deficiency of the trans-
porter and in clinical symptoms. These findings 
suggest that MCT1 deficiency is more prevalent 
than is apparent among previously described dis-
orders of ketone utilization. The heterozygous 
family members of patients with homozygous 
MCT1 loss-of-function mutations had no history 
of ketoacidosis, which strongly suggests that het-
erozygous mutations — and possibly even homo-
zygous mutations — in MCT1 give rise to keto-
acidosis only in conjunction with certain genetic 
and environmental factors. The varying number 
of episodes and long symptom-free intervals in 
both heterozygous and homozygous patients 
support this hypothesis. Future research will have 
to identify the factors involved in triggering the 
development of symptoms.
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